{"id":"NCT02105467","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)","officialTitle":"A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects With Chronic HCV GT1, GT4, and GT6 Infection.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06-05","primaryCompletion":"2015-02-26","completion":"2015-09-06","firstPosted":"2014-04-07","resultsPosted":"2016-04-12","lastUpdate":"2018-10-02"},"enrollment":421,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"Grazoprevir 100mg / Elbasvir 50 mg FDC","otherNames":[]},{"type":"DRUG","name":"Placebo to Grazoprevir / Elbasvir 50 mg FDC","otherNames":[]}],"arms":[{"label":"Immediate Treatment Group","type":"EXPERIMENTAL"},{"label":"Deferred Treatment Group","type":"PLACEBO_COMPARATOR"}],"summary":"This was an efficacy and safety study of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) in treatment-naive participants with chronic hepatitis C virus (HCV) genotype (GT) 1, 4, or 6 infection. Participants were randomly assigned (3:1 ratio) to immediate treatment or deferred treatment (placebo control). The primary efficacy hypothesis was that the proportion of participants receiving combination therapy in the Immediate Treatment Arm who achieve sustained viral response at 12 weeks after the end of study treatment (SVR12) is superior to 73%.","primaryOutcome":{"measure":"Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)","timeFrame":"Week 24 (12 weeks after the end of treatment)","effectByArm":[{"arm":"Immediate Treatment Group","deltaMin":94.6,"sd":null}],"pValues":[{"comp":"OG000","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["25909356","29461687","29404492","28193518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":316},"commonTop":["Headache","Fatigue","Nausea","Nasopharyngitis","Arthralgia"]}}